Crossmark

Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3

Crossref DOI link: https://doi.org/10.1007/s00417-022-05836-x

Published Online: 2022-10-07

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Feenstra, Helena M. A.

van Dijk, Elon H. C.

van Rijssen, Thomas J.

Tsonaka, Roula

Diederen, Roselie M. H.

Hoyng, Carel B.

Schlingemann, Reinier O.

Boon, Camiel J. F.
Funding

Funding for this research was provided by:

Stichting Blindenhulp

Stichting MaculaFonds

Retina Nederland Onderzoek Fonds

Stichting Blinden-Penning

Algemene Nederlandse Vereniging ter voorkoming van Blindheid

Landelijke Stichting voor Blinden en Slechtzienden

Rotterdamse Stichting Blindenbelangen

Stichting Leids Oogheelkundig Ondersteuningsfonds

Stichting voor Ooglijders

Universiteit Leiden (the Gisela Thier Fellowship)

Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VENI grant)
License Information

Text and Data Mining valid from 2022-10-07

Version of Record valid from 2022-10-07
More Information

Article History

Received: 11 June 2022

Revised: 23 August 2022

Accepted: 9 September 2022

First Online: 7 October 2022

Declarations

:

: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Institutional Review Board Committee approval was obtained from all participating centers before the start of the study. Ethics approval was obtained from the medical ethical committee of Leiden University Medical Center (NL59158.058.16).

: Informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below